CoChat

Lung Transplantation for Lymphangioleiomyomatosis in Japan

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Lung transplantation has been established as the definitive treatment option for patients with advanced lymphangioleiomyomatosis (LAM). However, the prognosis after registration and the circumstances of lung transplantation with sirolimus therapy have never been reported. METHODS: In this national survey, we analyzed data from 98 LAM patients registered for lung transplantation in the Japan Organ Transplantation Network. RESULTS: Transplantation was performed in 57 patients as of March 2014. Survival rate was 86.7% at 1 year, 82.5% at 3 years, 73.7% at 5 years, and 73.7% at 10 years. Of the 98 patients, 21 had an inactive status and received sirolimus more frequently than those with an active history (67% vs. 5%, p<0.001). Nine of twelve patients who remained inactive as of March 2014 initiated sirolimus before or while on a waiting list, and remained on sirolimus thereafter. Although the statistical analysis showed no statistically significant difference, the survival rate after registration tended to be better for lung transplant recipients than for those who awaited transplantation (p = 0.053). CONCLUSIONS: Lung transplantation is a satisfactory therapeutic option for advanced LAM, but the circumstances for pre-transplantation LAM patients are likely to alter with the use of sirolimus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0146749

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Kaplan-Meier calculated survival rate after lung transplantation for 57 patients with LAM. The median follow-up period was 1,085 days. The probability of survival at 1, 3, 5 and 10 years after lung transplantation was 86.7%, 82.5%, 73.7% and 73.7%, respectively.
Fig 1 Kaplan-Meier calculated survival rate after lung transplantation for 57 patients with LAM. The median follow-up period was 1,085 days. The probability of survival at 1, 3, 5 and 10 years after lung transplantation was 86.7%, 82.5%, 73.7% and 73.7%, respectively.CC BY · PubMed Central
Fig 2 Illustration of the periods of inactive status and sirolimus treatment while on the transplantation waiting list. A. Eight of 21 LAM patients with a history of inactive status had received lung transplants. Five of eight patients had a period during which they had been on the sirolimus treatment (we could not confirm the period of time in case 3*). The reason why a patient had been inactive is indicated at the right end of each illustration by: A, anxiety and fear about transplantation; C, comorbidity (cases 6 and 8, psychiatric disorder and case 3, thyroid tumor); F, family matter; M, participated in the MILES trial; NA, not available; and S, on sirolimus treatment. Although the cases 1 and 7 participated in the MILES trial, they were in the placebo group; the case 7 took sirolimus after the MILES trial. The clinical courses of cases 2, 4, 5, and 7 who took sirolimus, but their clinical courses were not stabilized sufficiently. B. Of twelve patients who were in an inactive status as of March 2014, nine initiated sirolimus treatment before registration (cases 2 and 6) or while on a waiting list (cases 3, 4, 5, 8, 9, 11, and 12). The reason for being inactive is presented with the same manner as in Fig 2A (A and M); S(S) indicates that a patient has been on sirolimus treatment and respiratory condition has improved or been stabilized.
Fig 2 Illustration of the periods of inactive status and sirolimus treatment while on the transplantation waiting list. A. Eight of 21 LAM patients with a history of inactive status had received lung transplants. Five of eight patients had a period during which they had been on the sirolimus treatment (we could not confirm the period of time in case 3*). The reason why a patient had been inactive is indicated at the right end of each illustration by: A, anxiety and fear about transplantation; C, comorbidity (cases 6 and 8, psychiatric disorder and case 3, thyroid tumor); F, family matter; M, participated in the MILES trial; NA, not available; and S, on sirolimus treatment. Although the cases 1 and 7 participated in the MILES trial, they were in the placebo group; the case 7 took sirolimus after the MILES trial. The clinical courses of cases 2, 4, 5, and 7 who took sirolimus, but their clinical courses were not stabilized sufficiently. B. Of twelve patients who were in an inactive status as of March 2014, nine initiated sirolimus treatment before registration (cases 2 and 6) or while on a waiting list (cases 3, 4, 5, 8, 9, 11, and 12). The reason for being inactive is presented with the same manner as in Fig 2A (A and M); S(S) indicates that a patient has been on sirolimus treatment and respiratory condition has improved or been stabilized.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. J Groetzner, 2004, Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression, J Heart Lung Transplant, 23, 632, 10.1016/S1053-2498(03)00309-7 · DOI · Paper page

Cited by

See all 37

Metadata

Authors
Ando, K., Okada, Y., Akiba, M., Kondo, T., Kawamura, T., Okumura, M., Chen, F., Date, H., Shiraishi, T., Iwasaki, A., Yamasaki, N., Nagayasu, T., Chida, M., Inoue, Y., Hirai, T., Seyama, K., Mishima, M., & Respiratory Failure Research Group of the Japanese Ministry of Health, L.
Affiliations
  • Juntendo University (JP)
  • Tohoku University (JP)
  • The University of Osaka (JP)
  • Kyoto University (JP)
  • Fukuoka University (JP)
  • Nagasaki University (JP)
  • Dokkyo University (JP)
  • Ministry of Health Labour and Welfare (JP)
Corresponding author
Seyama, Kuniaki
Venue
PLOS ONE
Published
2016-01-15
Volume
11
Issue
1
Pages
e0146749
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2247267173
Cited by
37
References
30
Citations by year
2025: 3 · 2024: 1 · 2023: 5 · 2022: 8 · 2021: 6 · 2020: 3 · 2019: 2 · 2018: 4 · 2017: 5
FWCI
2.95
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by)
Funders
  • Nihon University
  • Keio University
  • Ministry of Health, Labour and Welfare
  • University of Tokyo
  • Hokkaido University
  • Chiba University
  • Tokyo Women's Medical University
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Medical Imaging and Pathology Studies
Keywords
lymphangioleiomyomatosis, lung transplantation, rapamycin, transplant recipient survival, transplant waiting list
MeSH terms
Adult, Anti-Bacterial Agents, Female, Humans, Japan, Lung Neoplasms, Male, Middle Aged, Retrospective Studies, Survival Rate, Lung Transplantation, Lymphangioleiomyomatosis, Sirolimus, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lung Transplantation for Lymphangioleiomyomatosis in Japan. https://app.cochat.ai/papers/10.1371/journal.pone.0146749
The paper
Ando, K., Okada, Y., Akiba, M., Kondo, T., Kawamura, T., Okumura, M., Chen, F., Date, H., Shiraishi, T., Iwasaki, A., Yamasaki, N., Nagayasu, T., Chida, M., Inoue, Y., Hirai, T., Seyama, K., Mishima, M., & Respiratory Failure Research Group of the Japanese Ministry of Health, L. (2016). Lung Transplantation for Lymphangioleiomyomatosis in Japan. PLOS ONE. https://doi.org/10.1371/journal.pone.0146749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.